PMID: 11907167Mar 22, 2002Paper

3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain

The Journal of Pharmacology and Experimental Therapeutics
Altaf S DarveshGary A Gudelsky

Abstract

Oxidative and/or bioenergetic stress is thought to contribute to the mechanism of neurotoxicity of amphetamine derivatives, e.g., 3,4-methylenedioxymethamphetamine (MDMA). In the present study, the effect of MDMA on brain energy regulation was investigated by examining the effect of MDMA on brain glycogen and glucose. A single injection of MDMA (10-40 mg/kg, s.c.) produced a dose-dependent decrease (40%) in brain glycogen, which persisted for at least 1 h. MDMA (10 and 40 mg/kg, s.c.) also produced a significant and sustained increase in the extracellular concentration of glucose in the striatum. Subjecting rats to a cool ambient temperature of 17 degrees C significantly attenuated MDMA-induced hyperthermia and glycogenolysis. MDMA-induced glycogenolysis also was prevented by treatment of rats with the 5-hydroxytryptamine(2) (5-HT(2)) antagonists 6-methyl-1-(1-methylethyl)-ergoline-8 beta-carboxylic acid 2-hydroxy-1 methylprophyl ester maleate (LY-53,857; 3 mg/kg i.p.), desipramine (10 mg/kg i.p.), and iprindole (10 mg/kg i.p.). LY-53,857 also attenuated the MDMA-induced increase in the extracellular concentration of glucose as well as MDMA-induced hyperthermia. Amphetamine analogs (e.g., methamphetamine and parachloroamphetami...Continue Reading

References

Oct 1, 1972·Analytical Biochemistry·S R Nahorski, K J Rogers
Sep 1, 1973·Journal of Neurochemistry·S R Nahorski, K J Rogers
May 1, 1970·British Journal of Pharmacology·D A Hutchins, K J Rogers
Dec 1, 1980·Journal of Neuroscience Methods·G PaxinosP C Emson
Jul 29, 1998·Journal of Neurochemistry·S E StephansB K Yamamoto
Apr 12, 2001·Journal of Neurochemistry·W L NixdorfB K Yamamoto

❮ Previous
Next ❯

Citations

Aug 19, 2008·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Bryan K Yamamoto, Jamie Raudensky
Mar 7, 2003·European Journal of Pharmacology·Altaf S Darvesh, Gary A Gudelsky
Jun 14, 2003·Pharmacology & Therapeutics·Jeffrey M Brown, Bryan K Yamamoto
Jan 18, 2008·Nephrology·Milica NinkovićZivorad Malicević
Jun 27, 2006·The AAPS Journal·Maria S Quinton, Bryan K Yamamoto
Aug 7, 2004·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Milica NinkovićIvana Vasiljević
Jul 31, 2013·Life Sciences·Laura E HalpinBryan K Yamamoto
Nov 24, 2007·Pharmacology, Biochemistry, and Behavior·Gary A Gudelsky, Bryan K Yamamoto
Jul 13, 2004·The European Journal of Neuroscience·P Leon Brown, Eugene A Kiyatkin
Aug 16, 2005·Brain Research·Altaf S Darvesh, Gary A Gudelsky
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Iain S McGregorAndrew J Lawrence
Jan 13, 2005·The Journal of Pharmacology and Experimental Therapeutics·Daniel E RusyniakJon E Sprague
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jie YuanGeorge A Ricaurte
Aug 10, 2012·The Journal of Experimental Biology·Jorge J Pérez-MaceiraManuel Aldegunde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.